Pro Football Hall of Famer Dan Marino speaks candidly about his 2007 MASH diagnosis and why he is eager to share his health story. Through a new partnership with Novo Nordisk, he hopes to raise greater awareness about the importance of fatty liver disease management.
Hall of Famer Dan Marino opens up about MASH diagnosis, why he wants to share his health journey

Key Takeaways:
- Dan Marino was diagnosed with MASH in 2007.
- He collaborates with Novo Nordisk to address fatty liver disease awareness.
- Marino’s personal story emphasizes the importance of proactive health management.
- The campaign aims to encourage broader conversations about liver health.
Dan Marino’s Personal Health Milestone
In 2007, Pro Football Hall of Famer Dan Marino received news that would change the course of his post-NFL life: a MASH diagnosis. While public attention often focuses on legendary plays and endurance on the field, this diagnosis added a new dimension to his well-known career.
A Campaign for Awareness
Marino has teamed up with Novo Nordisk to shed light on fatty liver disease management. By participating in this campaign, he hopes to encourage people to pay closer attention to liver health, an issue that can often go unnoticed until later stages.
Why He’s Speaking Out
“I’m sharing my story so others can take notice,” Marino says, underlining his determination to see more people screened and informed. His goal is not only to inform the public about MASH but also to inspire conversations about overall health.
Fatty Liver Disease in Focus
With this partnership, Marino directs attention to a broader challenge: educating the public on fatty liver disease and the ways it can affect individuals’ longevity and well-being. MASH, which falls under the fatty liver disease spectrum, is a reminder that even renowned athletes can face unexpected health problems.
Looking Ahead
Dan Marino’s message resonates with his fans and the health community alike. By reflecting on his own 2007 diagnosis and working with Novo Nordisk, he shows how a personal narrative can galvanize a much larger campaign. He hopes others will be guided to take proactive steps in managing and monitoring their health, ultimately reducing the burden of fatty liver disease.